Ligand Pharmaceuticals Incorporated (LGND)

Ligand Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	51.46	124.45	-4.03	52.15	-33.36	57.14
Depreciation & Amortization	34.97	33.78	35.24	36.52	38.32	50.95
Other Amortization	6.67	3.22	2.61	1.98	6.26	21.53
Loss (Gain) From Sale of Assets	-	-	-	-2.12	-	-
Asset Writedown & Restructuring Costs	6.2	6.2	30.57	0.92	-	-
Loss (Gain) From Sale of Investments	-4.75	-167.13	-34.63	-47.68	-28.52	4.11
Loss (Gain) on Equity Investments	-	-	7.01	1.83	-	-
Stock-Based Compensation	56.7	46.85	41.09	25.74	50.88	38.78
Other Operating Activities	-20.8	14.67	-0.17	14.64	16.54	-36.71
Change in Accounts Receivable	-25.8	-21.74	-6.46	-2.6	55.32	-28.62
Change in Inventory	-2.61	4.99	9.62	-10.87	12.06	-0.43
Change in Accounts Payable	8.91	5.88	13.9	-4.7	-3.34	2.81
Change in Unearned Revenue	-0	-0.58	-1.31	0.42	-6.28	-17.87
Change in Income Taxes	-22.25	2.67	2.31	-1.78	1.58	-3.98
Change in Other Net Operating Assets	2.34	-3.89	1.29	-14.87	6.34	-8.93
Operating Cash Flow	91.03	49.36	97.05	49.58	137.85	78.8
Operating Cash Flow Growth	185.24%	-49.14%	95.75%	-64.04%	74.94%	44.36%

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Capital Expenditures	-0.41	-0.45	-1.82	-3.52	-12.35	-8.76
Cash Acquisitions	-782.85	-	-	-10.41	-	-
Divestitures	-8.09	-8.09	-	-	-	-
Sale (Purchase) of Intangibles	-	-	-	-	-	0.49
Investment in Securities	159.87	-349.73	-136.08	52.15	182.42	40.01
Other Investing Activities	-37.85	-19.05	-5.77	-49.91	-6.44	-1.22
Investing Cash Flow	-669.33	-377.32	-143.66	-11.68	163.62	30.52

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Long-Term Debt Issued	-	460	-	-	-	-
Long-Term Debt Repaid	-	-113.28	-0.03	-76.9	-261	-164.95
Net Debt Issued (Repaid)	504.18	346.72	-0.03	-76.9	-261	-164.95
Issuance of Common Stock	31.18	47.5	102.73	22.45	3.23	33.76
Repurchase of Common Stock	-82.45	-24.6	-5.14	-4.55	-8.24	-6.02
Other Financing Activities	91.79	58.6	-0.43	-0.95	-9.98	-0.56
Financing Cash Flow	544.69	428.22	97.14	-59.95	-275.99	-137.76

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Foreign Exchange Rate Adjustments	-2.39	2.36	-1.17	-	-	-
Net Cash Flow	-35.99	102.62	49.35	-22.05	25.48	-28.44

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	90.63	48.91	95.23	46.06	125.5	70.04
Free Cash Flow Growth	194.63%	-48.64%	106.76%	-63.30%	79.19%	39.72%
Free Cash Flow Margin	35.70%	18.24%	56.98%	35.07%	63.95%	29.00%
Free Cash Flow Per Share	4.21	2.41	5.21	2.59	7.44	4.06
Levered Free Cash Flow	62.45	87.09	100.79	46.03	136.93	37.03
Unlevered Free Cash Flow	63.45	88.76	102.2	46.2	137.33	32.6

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash Interest Paid	2.46	0.32	0.26	0.29	1.43	3.03
Cash Income Tax Paid	8.07	7.8	19.21	8.77	11.64	3.72
Change in Working Capital	-39.42	-12.67	19.36	-34.4	65.68	-57

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Oct 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 4, 2026

Data Sources Report a data error